• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Small-molecule inhibitor may reduce chemotherapy-associated metastases [PreClinical]

byChristine YoonandJessica Lau
August 27, 2017
in Oncology, Preclinical, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In a mouse model of breast cancer, treatment with the chemotherapy paclitaxel (Ptx) enhanced tumor cell dissemination and the formation of micrometastatic lung lesions.

2. Prophylactic treatment with rebastinib diminished Ptx-driven metastatic progression by reducing levels of circulating tumor cells (CTCs) in the blood.

Evidence Rating Level: 2 (Good)

Study Rundown: Though chemotherapeutic agents are widely used as neoadjuvant therapies for treating a variety of cancers including breast cancer, increasing scientific evidence suggests that these drugs may in fact result in disease progression. In this work, the authors demonstrated that Ptx treatment enhanced the metastasis of breast cancer, then investigated the efficacy of a secondary treatment to mitigate this effect.

Using mice with spontaneous or transplanted breast tumors, the authors demonstrated that treatment with Ptx diminished tumor volume. However, treatment also enhanced metastatic dissemination, as measured by the number of hematogenous CTCs, and resulted in a higher rate of lung metastasis. This effect was accompanied by a higher tumor microenvironment of metastasis (TMEM) score, which quantifies the microanatomical sites that are known to be associated with hematogenous entry of cancer cells and serves as clinical marker of metastasis in breast cancer patients. When mice received pretreatment with rebastinib, a known inhibitor of the TIE2 receptor that is expressed by TMEM-associated macrophages, TMEM scores did not significantly change. Nonetheless, this combination therapy diminished overall CTC levels.

While this work provides preliminary evidence that treatment with rebastinib during chemotherapy can diminish CTC levels, future work should focus on directly demonstrating lower incidence of metastasis and improved overall survival. Additionally, safety studies will need to determine proper dosage and treatment regimen to maximize efficacy while minimizing off-target effects.

Click to read the study in Science Translational Medicine 

RELATED REPORTS

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

Relevant Reading: Tumor Microenvironment of Metastasis in Human Breast Carcinoma: A Potential Prognostic Marker Linked to Hematogenous Dissemination

In-Depth [animal study]: Two mouse models of breast cancer were established for these experiments: (1) spontaneous breast tumors developed in FVB transgenic mice expressing the Polyoma Virus Middle-T (PyMT) antigen under the control of mammary tumor virus long terminal repeat (MMTV-LTR), and (2) late-stage carcinomas from spontaneous PyMT tumors were transplanted into 5–6 week old recipient FVB mice. Both groups received Ptx intravenously at 10 mg/mL every 5 days for a total of 3 doses.

As compared to vehicle control treatment, Ptx-treated mice demonstrated a minor decrease in tumor volume (p = 0.08) and nearly two-fold increases in TMEM score (p < 0.001), as measured by colocalization of MENA, IBA1, and endomucin via immunohistological staining. Levels of CTCs were measured prior to sacrifice on day 15, and results indicated an increase in CTCs after Ptx treatment relative to the control (p < 0.005). Quantifications of disseminated single cells and micrometastatic foci (clusters with >5 cancer cells) were determined through H&E staining. Ptx treatment resulted in nearly twice as many disseminated single cells (p = 0.008) and increased incidence and number of lung metastases.

To determine the effects of rebastinib on Ptx-induced metastatic progression, mice were treated daily through oral administration of 10 mg/kg rebastinib for 4 days prior to Ptx administration and throughout the chemotherapy regimen. Though TMEM scores did not significantly differ between the Ptx-only and Ptx+rebastinib groups, the combination treatment significantly lowered CTC levels in the blood (p = 0.0012).

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chemotherapypaclitaxel
Previous Post

2 Minute Medicine Rewind August 21, 2017

Next Post

CRISPR-Cas9 corrects hypertrophic cardiomyopathy gene mutation in human preimplantation embryos [PreClinical]

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

June 30, 2022
#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia
StudyGraphics

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

June 12, 2022
#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
StudyGraphics

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

May 18, 2022
Dacomitinib may be effective in EGFR-associated lung cancer
Chronic Disease

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

May 9, 2022
Next Post

CRISPR-Cas9 corrects hypertrophic cardiomyopathy gene mutation in human preimplantation embryos [PreClinical]

Head circumference better predicts labor dystocia than weight

Racial and ethnic differences in NICU care delivery

Intrapartum serum prolactin may predict risk of postpartum diabetes

2 Minute Medicine Rewind August 28, 2017

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early exposure to allergenic foods may reduce incidence of long-term food allergy
  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.